Introduction
Acute myeloid leukemia (AML) is one of the myeloid neoplasms characterized by immature progenitors proliferation and accumulation [1] . As a result of the poor survival rate of AML patients, treatment resistance, frequent relapses and numerous secondary conditions of AML, several studies focused on this disease in order to extend the existing knowledge [2, 3] . Nowadays, cytogenetics and molecular genetics, but not only, are mandatory in AML management, as a consequence of their clinical impact [2] [3] [4] [5] . Several chromosomal rearrangements and aneu-ploidies were included in the latest AML classification [6] and also in the 2017 version of the European LeukemiaNet (ELN) Risk Stratification by Genetics [7] . Some of them may be identified by cytogenetic investigation while others need molecular approaches. Banding cytogenetic and fluorescent in situ hybridization (FISH) were routinely used for the investigation of chromosomal abnormalities in leukemia. Considering that cytogenetic analysis has a low resolution and FISH investigates only large and common lesions, a multiplex assay, namely Multiplex Ligation-dependent Probe Amplification (MLPA) was proposed for the detection of chromosomal aberrations, represented by deletions or duplications that may lead to copy number alterations in genomic DNA. MLPA is a fast, useful and cost-effective technique that can be used in order to detect copy number aberrations (CNAs) and also aneuploidies for leukemia patients, but not only [8] [9] [10] . In addition to the chromosomal rearrangements and aneuploidies, several somatically acquired mutations are described in AML patients, most of them being involved in the evolution of AML, but still, currently, few of them are included in the AML classification and ELN risk-stratification [6, 7] . Briefly, according to the moment during leukemogenesis, two groups of somatically acquired mutations were described: early acquired mutations [such as DNA methyltransferase 3A gene (DNMT3A) etc.] and late acquired mutations [such as FMS-like Tyrosine Kinase 3 (FLT3), Nucleophospmin 1 (NPM1) genes, etc.] [2, 3] . The consequences of FLT3 and NPM1 mutations are well-known [1] [2] [3] [4] [5] [6] [7] 11] . Early acquired mutations remain a continuous challenge for AML because these may persist after therapy, leading to clonal expansion during hematologic remission, and eventually to relapse [3] . Analysis of these mutations requires the choice of the most effective, specific and sensitive molecular techniques taking into account the type of mutation, its size and locus, percentage of the mutant clone, and of course the available infrastructure.
Here, we present a rare AML case with four somatic mutations, identified according to our algorithm for the analysis of CNAs, aneuploidies and somatic mutations.
Material and Methods

Clinical report
We investigated a 64-year-old male patient diagnosed with AML classified as M1 according to the French-American-British classification. Patient complaints were: asthenia, fatigability, loss of appetite and weight loss (10 kilograms in 3 weeks). Flow cytometry immunophenotyping revealed the presence of 33.8% myeloid elements, 4% lymphocytes, 2.5% erythroblasts, 35% atypical monocytes [positive for CD33(58%), CD15, CD11b(83%), CD11c, CD64, CD14(14.5%), CD38, CD123, CD4, HLA-DR and negative for CD16, CD36, CD34, CD117] and 24% myeloblasts [positive for CD13(85%), CD33, CD15(3%), CD11c(50%), CD64(18.5%), HLA-DR(var), CD34(5%), CD117, CD38, CD123, CD7(75%), CD4(18.5%) and negative for CD3, CD22, CD10, CD14, CD16, CD36, CD11b]. The treatment with low dose of Cytosar was initiated and peripheral blood and bone marrow were collected and sent to the Genetics Department. The workflow of investigation performed in AML cases is based on recommendations of Döhner et al. [7] and is as follow: cytogenetic, gene mutations analysis (including FLT3, NPM1, TP53, RUNX1), additional procedures on diagnosis: MLPA. Molecular investigation was started in parallel with cytogenetic analysis in order to have the results in a timely manner.
Cytogenetic analysis
Cytogenetic analysis was performed from bone marrow and peripheral blood. GTG-banding (G-bands by Trypsin and Giemsa) was performed and described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2013.
Somatic mutation analysis FLT3-ITD, FLT3-D835 (c.2503 G>C/A/T;
c.2504 A>C/T; c.2505 T>A/G), DNMT3A (codon R882) and NPM1 (c.863_864ins) mutations were analyzed using specific primers and the PCR, RFLP-PCR and ARMS-PCR techniques as previously described [12] [13] [14] . In order to confirm and quantify the presence of the mutant clone, we performed fragment analysis for FLT3-ITD and NPM1 mutations, as previously reported [15] , on an Applied Biosystems 3500 Genetic Analyzer. The detailed protocols used with locally adapted and optimized conditions are mentioned in Table I . In order to confirm the mutations found by RFPL-PCR (FLT3-D835 and DNMT3A), we performed sequencing as previously described [16] .
Next-generation sequencing analysis (NGS)
NGS analysis was performed using the Ion Proton system and Ion AmpliSeq™ AML Research Panel (ThermoFisher Scientific), a four-pool panel containing 237 amplicons from 19 different genes involved in AML. Interested loci from different genes such as GATA2, KRAS, NRAS, IDH1, IDH2, ASXL1, TET2, CEBPA, RUNX1, TP53, and others were analyzed in order to find different mutation types. Ion Reporter™ Software (ThermoFisher Scientific) was used to analyze the results.
MLPA analysis
The patient's DNA was extracted from peripheral blood (PureLink GenomicDNA, ThermoFisher). In order to detect possible aneuploidies, as previously described [10] , as well as subtelomeric CNAs and the most common and clinically significant CNAs in AML, we performed MLPA analysis using SALSA MLPA P036, P070 and P377 probemixes (MRC-Holland). After capillary electrophoresis (Applied Biosystems 3500 Genetic Analyzer), Coffalyser.net software was used to interpret the results using three reference DNA samples (without CNAs).
Results
Cytogenetic analysis did not reveal structural or numerical chromosomal anomalies. Somatic mutation analysis was performed for FLT3-ITD (PCR), FLT3-D835 (RFLP-PCR), NPM1 (ARMS-PCR) and DNMT3A (RFLP-PCR), the patient being heterozygous for FLT3-ITD and D835, NPM1 and DNMT3A R882C. The specific inserted nucleotides (A-D mutation type) were not determined by ARMS-PCR technique due to possible cross-reactions between the different NPM1 primers used (electrophoresis results in Figure 1 ). We continued with confirming our somatic mutation results using different techniques. Fragment analysis was performed for FLT3-ITD and NPM1 mutations and sequencing for FLT3-D835 and DNMT3A R882C mutations. Fragment analysis confirmed the previous results, and the variant allele ratio (VAR) for FLT3-ITD was 86% and 42% for NPM1 c.863_864ins (Figure 2 ). The DNMT3A R882C and FLT3-D835 (c.2504A>T, D835V) mutations were also confirmed by capillary sequencing (Figure 3 ). Besides these two mutations, no other variations in the amplicon were found. Taking into account that we found four somatic mutations in our patient we supposed that our AML case may also associate other abnormalities (which can be useful for the clinical management of the patient) we decided to perform NGS. After data analysis, we obtained five vari- (table I) The last three variants, rs1042522, rs2276599 and rs2454206 were confirmed by TaqMan assays (ThermoFisher Scientific) and the 7500 Fast Dx Real-Time PCR system. Additionally, the patient showed no CNAs following the MLPA analysis ( Figure 4 ).
Fig. 1. Electrophoresis results for the somatic mutations investigated by PCR, RFLP-PCR and ARMS PCR. 1L-LEFT: M-Marker 100bp, A-FLT3 ITD heterozygous genotype, B-FLT3 D835 heterozygous genotype, C-DNMT3A with AciI enzyme-heterozygous genotype, D-DNMT3A with AluI enzyme-heterozygous genotype. 1R-RIGHT: M-Marker 50bp, N-normal primer, A-A primer
Discussions
In this study, we briefly presented our proposed algorithm for the analysis of CNAs, aneuploidies and gene mutations focusing on a rare patient with AML. Our results showed that the patient had an intermediate risk according to the 2017 ELN risk stratification (FLT3-ITD high and mutated NPM1). Based on our findings and according to the World health organization 2016 classification, we considered our case as AML with recurrent genetic abnormalities [6] . Even though the previously described PCR and ARMS-PCR protocols [12, 14] are easy to use, inexpensive and can be performed with basic infrastructure, we recommend the fragment analysis for FLT3-ITD and NPM1 c.863_864ins, the biggest advantage being the possibility to quantify the mutant clone and monitor its dynamics over time. For NPM1 c.863_864ins, neither ARMS-PCR [14] nor fragment analysis can distinguish between the inserted oligonucleotides, therefore being unable to specify the type of NPM1 mu- 
